NO317236B1 - Insulinutskillende cellelinjer, fremgangsmate for fremstilling og anvendelse derav - Google Patents

Insulinutskillende cellelinjer, fremgangsmate for fremstilling og anvendelse derav Download PDF

Info

Publication number: NO317236B1
Authority: NO; Norway
Prior art keywords: cells; insulin; cell line; igf; gene
Prior art date: 1993-09-30

Application number

NO19961268A

Other languages

English (en)

Norwegian (no)

Other versions

NO961268L (no

NO961268D0 (no

Inventor

Maryam Asfari

Paul Czernichow

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-30

Filing date

1996-03-29

Publication date

2004-09-27

1996-03-29 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

1996-03-29 Publication of NO961268L publication Critical patent/NO961268L/no

1996-03-29 Publication of NO961268D0 publication Critical patent/NO961268D0/no

2004-09-27 Publication of NO317236B1 publication Critical patent/NO317236B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 20
210000004027 cell Anatomy 0.000 claims abstract description 53
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 44
108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims abstract description 40
102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims abstract description 26
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims abstract description 24
102000004877 Insulin Human genes 0.000 claims abstract description 22
108090001061 Insulin Proteins 0.000 claims abstract description 22
229940125396 insulin Drugs 0.000 claims abstract description 22
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 18
239000008103 glucose Substances 0.000 claims abstract description 18
230000003248 secreting effect Effects 0.000 claims abstract description 10
230000035755 proliferation Effects 0.000 claims abstract description 8
230000001419 dependent effect Effects 0.000 claims abstract description 7
239000000017 hydrogel Substances 0.000 claims abstract description 4
108090000623 proteins and genes Proteins 0.000 claims description 13
229930193140 Neomycin Natural products 0.000 claims description 12
229960004927 neomycin Drugs 0.000 claims description 12
210000004153 islets of langerhan Anatomy 0.000 claims description 8
238000005538 encapsulation Methods 0.000 claims description 7
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 7
229960002963 ganciclovir Drugs 0.000 claims description 7
230000006801 homologous recombination Effects 0.000 claims description 6
238000002744 homologous recombination Methods 0.000 claims description 6
238000011282 treatment Methods 0.000 claims description 5
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
239000012528 membrane Substances 0.000 claims description 4
239000013612 plasmid Substances 0.000 claims description 4
238000001890 transfection Methods 0.000 claims description 4
241000700159 Rattus Species 0.000 claims description 3
102000006601 Thymidine Kinase Human genes 0.000 claims description 3
108020004440 Thymidine kinase Proteins 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 3
159000000007 calcium salts Chemical class 0.000 claims description 3
239000000835 fiber Substances 0.000 claims description 3
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
239000000853 adhesive Substances 0.000 claims description 2
230000001070 adhesive effect Effects 0.000 claims description 2
238000002955 isolation Methods 0.000 claims description 2
235000010413 sodium alginate Nutrition 0.000 claims description 2
229940005550 sodium alginate Drugs 0.000 claims description 2
239000000661 sodium alginate Substances 0.000 claims description 2
230000001629 suppression Effects 0.000 claims description 2
230000003612 virological effect Effects 0.000 claims description 2
210000004457 myocytus nodalis Anatomy 0.000 claims 9
239000003795 chemical substances by application Substances 0.000 claims 3
230000003100 immobilizing effect Effects 0.000 claims 2
238000012258 culturing Methods 0.000 claims 1
239000000499 gel Substances 0.000 claims 1
239000003349 gelling agent Substances 0.000 claims 1
239000000725 suspension Substances 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract description 4
238000010353 genetic engineering Methods 0.000 abstract description 3
102000030595 Glucokinase Human genes 0.000 abstract description 2
108010021582 Glucokinase Proteins 0.000 abstract description 2
238000004220 aggregation Methods 0.000 abstract 1
230000002776 aggregation Effects 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 description 14
238000002054 transplantation Methods 0.000 description 11
230000004663 cell proliferation Effects 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
230000006378 damage Effects 0.000 description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
230000003914 insulin secretion Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
108010051696 Growth Hormone Proteins 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 2
108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102100038803 Somatotropin Human genes 0.000 description 2
102000023732 binding proteins Human genes 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
230000004222 uncontrolled growth Effects 0.000 description 2
108700028369 Alleles Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
102100024819 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
101150032953 ins1 gene Proteins 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
102000028416 insulin-like growth factor binding Human genes 0.000 description 1
108091022911 insulin-like growth factor binding Proteins 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000008775 paternal effect Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1
238000002689 xenotransplantation Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Obesity (AREA)
Transplantation (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Oral & Maxillofacial Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

NO19961268A 1993-09-30 1996-03-29 Insulinutskillende cellelinjer, fremgangsmate for fremstilling og anvendelse derav NO317236B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9311687A FR2710654B1 (fr)	1993-09-30	1993-09-30	Nouvelles lignées de cellules sécrétrices d'insuline, leurs procédés d'obtention par voie de manipulation génétique et leur utilisation chez des sujets diabétiques sous forme protégée.
PCT/FR1994/001129 WO1995009231A1 (fr)	1993-09-30	1994-09-27	Lignees de cellules secretrices d'insuline, procedes d'obtention et utilisation

Publications (3)

Publication Number	Publication Date
NO961268L NO961268L (no)	1996-03-29
NO961268D0 NO961268D0 (no)	1996-03-29
NO317236B1 true NO317236B1 (no)	2004-09-27

Family

ID=9451437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19961268A NO317236B1 (no)	1993-09-30	1996-03-29	Insulinutskillende cellelinjer, fremgangsmate for fremstilling og anvendelse derav

Country Status (17)

Country	Link
US (1)	US5902577A (ko)
EP (1)	EP0721500B1 (ko)
JP (2)	JPH09503662A (ko)
KR (2)	KR100463366B1 (ko)
CN (1)	CN1078248C (ko)
AT (1)	ATE299930T1 (ko)
AU (1)	AU688383B2 (ko)
BR (1)	BR9407682A (ko)
CA (1)	CA2172997A1 (ko)
DE (1)	DE69434433T2 (ko)
DK (1)	DK0721500T3 (ko)
ES (1)	ES2243929T3 (ko)
FI (1)	FI961440A (ko)
FR (1)	FR2710654B1 (ko)
HU (1)	HU219826B (ko)
NO (1)	NO317236B1 (ko)
WO (1)	WO1995009231A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5427940A (en) *	1991-06-03	1995-06-27	Board Of Regents, The University Of Texas System	Engineered cells producing insulin in response to glucose
US5744327A (en) *	1990-02-20	1998-04-28	Board Of Regents, The University Of Texas System	Methods for producing insulin in response to non-glucose secretagogues
US5792656A (en) *	1991-06-03	1998-08-11	Board Of Regents, The University Of Texas System	Methods of preparing genetically engineered cells that produce insulin in response to glucose
US6642003B2 (en)	2001-08-02	2003-11-04	Cedars-Sinai Medical Center	Human glucose-dependent insulin-secreting cell line
CA2692325C (en) *	2001-12-07	2015-10-20	Geron Corporation	Islet cells from human embryonic stem cells
US7141240B2 (en) *	2002-03-12	2006-11-28	Cedars-Sinai Medical Center	Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
WO2007149182A2 (en)	2006-06-19	2007-12-27	Geron Corporation	Differentiation and enrichment of islet-like cells from human pluripotent stem cells
US10767164B2 (en)	2017-03-30	2020-09-08	The Research Foundation For The State University Of New York	Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN109957539A (zh) *	2017-12-14	2019-07-02	深圳先进技术研究院	一种人造胰岛组织及其制备和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4229526B4 (de) *	1992-09-07	2006-02-16	Schrezenmeir, Jürgen, Dr.	Vorrichtung zur Aufnahme und zum Einbringen von biologisch aktiven Geweben oder Zellen in den menschlichen Körper

1993
- 1993-09-30 FR FR9311687A patent/FR2710654B1/fr not_active Expired - Fee Related
1994
- 1994-09-27 AT AT94928920T patent/ATE299930T1/de not_active IP Right Cessation
- 1994-09-27 KR KR10-2004-7001293A patent/KR100463366B1/ko not_active IP Right Cessation
- 1994-09-27 WO PCT/FR1994/001129 patent/WO1995009231A1/fr active IP Right Grant
- 1994-09-27 DK DK94928920T patent/DK0721500T3/da active
- 1994-09-27 CN CN94193910A patent/CN1078248C/zh not_active Expired - Fee Related
- 1994-09-27 AU AU78157/94A patent/AU688383B2/en not_active Ceased
- 1994-09-27 DE DE69434433T patent/DE69434433T2/de not_active Expired - Lifetime
- 1994-09-27 US US08/619,612 patent/US5902577A/en not_active Expired - Lifetime
- 1994-09-27 HU HU9600789A patent/HU219826B/hu not_active IP Right Cessation
- 1994-09-27 CA CA002172997A patent/CA2172997A1/en not_active Abandoned
- 1994-09-27 EP EP94928920A patent/EP0721500B1/fr not_active Expired - Lifetime
- 1994-09-27 BR BR9407682A patent/BR9407682A/pt not_active Application Discontinuation
- 1994-09-27 KR KR1019960701650A patent/KR100432851B1/ko not_active IP Right Cessation
- 1994-09-27 JP JP7510148A patent/JPH09503662A/ja active Pending
- 1994-09-27 ES ES94928920T patent/ES2243929T3/es not_active Expired - Lifetime
1996
- 1996-03-29 NO NO19961268A patent/NO317236B1/no unknown
- 1996-03-29 FI FI961440A patent/FI961440A/fi not_active Application Discontinuation
2005
- 2005-03-10 JP JP2005066427A patent/JP2005185293A/ja active Pending

Also Published As

Publication number	Publication date
FI961440A0 (fi)	1996-03-29
FR2710654A1 (fr)	1995-04-07
JP2005185293A (ja)	2005-07-14
HU219826B (hu)	2001-08-28
CA2172997A1 (en)	1995-04-06
FI961440A (fi)	1996-03-29
US5902577A (en)	1999-05-11
AU7815794A (en)	1995-04-18
HUT75985A (en)	1997-05-28
HU9600789D0 (en)	1996-05-28
NO961268L (no)	1996-03-29
FR2710654B1 (fr)	1995-12-22
KR20040017357A (ko)	2004-02-26
NO961268D0 (no)	1996-03-29
KR100463366B1 (ko)	2004-12-29
DE69434433D1 (de)	2005-08-25
CN1078248C (zh)	2002-01-23
ES2243929T3 (es)	2005-12-01
AU688383B2 (en)	1998-03-12
BR9407682A (pt)	1997-02-04
DK0721500T3 (da)	2005-10-17
EP0721500A1 (fr)	1996-07-17
KR100432851B1 (ko)	2004-11-06
CN1134724A (zh)	1996-10-30
EP0721500B1 (fr)	2005-07-20
WO1995009231A1 (fr)	1995-04-06
DE69434433T2 (de)	2006-04-20
JPH09503662A (ja)	1997-04-15
ATE299930T1 (de)	2005-08-15
KR960705028A (ko)	1996-10-09

Publication	Publication Date	Title
Weir et al.	1997	Scientific and political impediments to successful islet transplantation
CA2188648A1 (en)	1995-11-09	In vitro growth of functional islets of langerhans and in vivo uses thereof
JP2005185293A (ja)	2005-07-14	インシュリン分泌細胞系、その製造方法と使用
JPH11514877A (ja)	1999-12-21	機能性ランゲルハンス島のインビトロ成長およびそのインビボの使用
US20050042746A1 (en)	2005-02-24	Growing xenotransplant material in culture
Schrezenmeir et al.	1993	Long-term function of porcine islets and single cells embedded in barium-alginate matrix
US20090110669A1 (en)	2009-04-30	Methods for improving cell line activity in immunoisolation devices
JP2000139455A (ja)	2000-05-23	ランゲルハンス島の培養及び島自己移植島再生方法
Li et al.	2023	Stem cells therapy for diabetes: from past to future
AU2003238760B2 (en)	2008-07-31	Porcine islets cultured with porcine sertoli cells for xenotransplantation
JP3115179B2 (ja)	2000-12-04	ハイブリット型人工膵臓
Cheng et al.	2023	Engineering strategies of islet products for endocrine regeneration
AU2002334485B2 (en)	2007-04-19	Growing xenotransplant material in culture
WO2004031372A1 (ja)	2004-04-15	グルコース感受性により改変されたインスリンを分泌する不死化肝細胞株
FLORIDA	0	In vitro growth of functional islets of Langerhans and in vivo uses thereof
NZ519540A (en)	2005-05-27	Aggregates of porcine islets and porcine Sertoli cells for xenotransplantation for the treatment of diabetes, and method of forming such aggregates
AU2002334485A1 (en)	2003-06-26	Growing xenotransplant material in culture
MXPA98003263A (en)	1998-11-16	In vitro growth of functional langerhans yuso in vivo de los mis